

*Contains Nonbinding Recommendations*  
*Draft – Not for Implementation*  
**Draft Guidance on Belumosudil Mesylate**  
**October 2024**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

---

<b>Active Ingredient:</b>	Belumosudil mesylate
<b>Dosage Form:</b>	Tablet
<b>Route:</b>	Oral
<b>Strength:</b>	EQ 200 mg Base
<b>Recommended Study:</b>	One in vivo bioequivalence study with pharmacokinetic endpoints
1.	Type of study: Fed Design: Single-dose, two-treatment, two-period crossover in vivo Strength: EQ 200 mg Base Subjects: Healthy males and healthy females not of reproductive potential Additional comments: Male subjects with female partners of reproductive potential should use effective contraception during the study and for one week after the last dose. Exclude subjects with abnormal liver function tests and monitor liver function during the study.
<b>Analyte to measure:</b>	Belumosudil in plasma
<b>Bioequivalence based on (90% CI):</b>	Belumosudil
<b>Waiver request of in vivo testing:</b>	Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution>. Conduct comparative dissolution testing on 12 dosage units for each of the test product and reference listed drug (RLD) products.<sup>1</sup> Specifications will be determined upon review of the abbreviated new drug application.

---

**Document History:** Recommended May 2023; Revised October 2024

**Unique Agency Identifier:** PSG\_214783

---

<sup>1</sup> If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions*.